{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:56:34Z","timestamp":1781618194955,"version":"3.54.5"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Hypothesis<\/jats:title>\n                    <jats:p>Eosinophilia has not been highlighted in clozapine-induced adverse inflammatory events, as it is often asymptomatic and self-limiting, while drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome occurs rarely. This study aimed to reveal the temporal relationships between eosinophilia and other inflammatory events during clozapine initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>The temporal relationships between eosinophilia and other inflammatory events were evaluated among 241 patients with schizophrenia treated with clozapine for the first time at 7 hospitals. Risk factors for eosinophilia were investigated among preceding inflammatory events and other clinical characteristics. Furthermore, patients with eosinophilia were stratified by the severity of adverse inflammatory events and their clinical characteristics were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>Of the 54 patients who experienced inflammatory adverse events, 27 (50%) developed eosinophilia. In all but 1 patient, clinical symptoms of inflammatory adverse events preceded eosinophilia. In contrast, of the 187 patients without inflammatory events, 21 (11%) developed eosinophilia. Multivariate analysis revealed that more severe preceding inflammatory adverse events were associated with a greater risk of eosinophilia. The median time to the first detection of eosinophilia and peak eosinophil count occurred significantly earlier in patients with severe adverse events than in asymptomatic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In most cases, eosinophilia developed after the onset of inflammatory symptoms. Preceding inflammation was associated with the development of clozapine-induced eosinophilia. Eosinophilia may not be suitable as an early detection marker of severe inflammatory adverse effects. These findings enhanced our understanding of the involvement of eosinophilia in clozapine-induced inflammatory events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbae213","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T23:27:14Z","timestamp":1733182034000},"source":"Crossref","is-referenced-by-count":8,"title":["Relationship Between Clozapine-Induced Inflammation and Eosinophilia: A Retrospective Cohort Study"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1184-8918","authenticated-orcid":false,"given":"Yuki","family":"Kikuchi","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Graduate School of Medicine, Tohoku University , Sendai, Miyagi, 980-8574 ,","place":["Japan"]},{"name":"Department of Psychiatry, Kodama Hospital , Ishinomaki, Miyagi, 986-0873 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Asahi General Hospital , Asahi, 289-2511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Ito","sequence":"additional","affiliation":[{"name":"National Hospital Organization Hanamaki Hospital , Hanamaki, 025-0033 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yada","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Okayama Psychiatric Medical Center , Okayama, 700-0915 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Tanifuji","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kodama Hospital , Ishinomaki, Miyagi, 986-0873 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Tohoku University Hospital , Sendai, Miyagi, 980-8574 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2628-880X","authenticated-orcid":false,"given":"Hiroaki","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Graduate School of Medicine, Tohoku University , Sendai, Miyagi, 980-8574 ,","place":["Japan"]},{"name":"Department of Psychiatry, Tohoku University Hospital , Sendai, Miyagi, 980-8574 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"2026011701164693700_CIT0001","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted, and how can it be avoided","volume":"74","author":"Nielsen","year":"2013","journal-title":"J Clin Psychiatry."},{"key":"2026011701164693700_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2019.07.040","article-title":"Clinical determinants of fever in clozapine users and implications for treatment management: a narrative review","volume":"211","author":"Verdoux","year":"2019","journal-title":"Schizophr Res."},{"key":"2026011701164693700_CIT0003","first-page":"466","article-title":"High risk of eosinophilia in women treated with clozapine","volume":"54","author":"Banov","year":"1993","journal-title":"J Clin Psychiatry."},{"key":"2026011701164693700_CIT0004","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3109\/00048679709065515","article-title":"Eosinophilia after commencement of clozapine treatment","volume":"31","author":"Chatterton","year":"1997","journal-title":"Aust N Z J Psychiatry."},{"key":"2026011701164693700_CIT0005","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/JCP.0000000000000387","article-title":"The effect of clozapine on hematological indices: a 1-year follow-up study","volume":"35","author":"Lee","year":"2015","journal-title":"J Clin Psychopharmacol."},{"key":"2026011701164693700_CIT0006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.schres.2023.06.003","article-title":"Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: a retrospective chart review of seven hospitals","volume":"268","author":"Kikuchi","year":"2024","journal-title":"Schizophr Res."},{"key":"2026011701164693700_CIT0007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JCP.0000000000001902","article-title":"Clozapine-associated eosinophilia at a movement disorders clinic","volume":"44","author":"Mohammadzadeh","year":"2024","journal-title":"J Clin Psychopharmacol."},{"key":"2026011701164693700_CIT0008","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/02698811211021587","article-title":"Unravelling cases of clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) in patients reported otherwise: a systematic review","volume":"35","author":"de Filippis","year":"2021","journal-title":"J Psychopharmacol."},{"key":"2026011701164693700_CIT0009","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/17512433.2020.1787831","article-title":"Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review","volume":"13","author":"de Filippis","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026011701164693700_CIT0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.schres.2021.07.023","article-title":"Core clinical manifestations of clozapine-related DRESS syndrome: a network analysis","volume":"243","author":"de Filippis","year":"2022","journal-title":"Schizophr Res."},{"key":"2026011701164693700_CIT0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.euroneuro.2022.04.009","article-title":"Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases","volume":"60","author":"de Filippis","year":"2022","journal-title":"Eur Neuropsychopharmacol."},{"key":"2026011701164693700_CIT0012","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41537-023-00412-6","article-title":"Slower clozapine titration is associated with delayed onset of clozapine-induced fever among Japanese patients with schizophrenia","volume":"9","author":"Kikuchi","year":"2023","journal-title":"Schizophrenia"},{"key":"2026011701164693700_CIT0013","doi-asserted-by":"crossref","first-page":"115810","DOI":"10.1016\/j.psychres.2024.115810","article-title":"Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia","volume":"334","author":"Kikuchi","year":"2024","journal-title":"Psychiatry Res."},{"key":"2026011701164693700_CIT0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy."},{"key":"2026011701164693700_CIT0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry."},{"key":"2026011701164693700_CIT0016","doi-asserted-by":"crossref","first-page":"976","DOI":"10.4088\/JCP.09m05024yel","article-title":"Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls","volume":"71","author":"Ronaldson","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"2026011701164693700_CIT0017","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/phar.2887","article-title":"A systematic review of clozapine-associated inflammation and related monitoring","volume":"43","author":"Leung","year":"2023","journal-title":"Pharmacotherapy."},{"key":"2026011701164693700_CIT0018","doi-asserted-by":"crossref","first-page":"1366621","DOI":"10.3389\/fpsyt.2024.1366621","article-title":"Patterns of C-reactive protein trends during clozapine titration and the onset of clozapine-induced inflammation: a case series of weekly and daily C-reactive protein monitoring","volume":"15","author":"Kikuchi","year":"2024","journal-title":"Front Psychiatry."},{"key":"2026011701164693700_CIT0019","first-page":"1","article-title":"Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals","volume":"1","author":"Kikuchi","year":"2024","journal-title":"Br J Psychiatry."},{"key":"2026011701164693700_CIT0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol."},{"key":"2026011701164693700_CIT0021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.9758\/cpn.2013.11.2.103","article-title":"Eosinophilia, pleural effusion, hepatitis, and jaundice occurring early in clozapine treatment","volume":"11","author":"Kang","year":"2013","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"2026011701164693700_CIT0022","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PRA.0000000000000621","article-title":"A case report of clozapine-induced pleural effusion in a 28-year-old Chinese male","volume":"28","author":"Wolfe","year":"2022","journal-title":"J Psychiatr Pract."},{"key":"2026011701164693700_CIT0023","doi-asserted-by":"crossref","first-page":"111104","DOI":"10.1016\/j.brainresbull.2024.111104","article-title":"The effect of clozapine on immune-related biomarkers in schizophrenia patients [published correction appears in Brain Res Bull. 2024;16:111127]","volume":"218","author":"Shao","year":"2024","journal-title":"Brain Res Bull."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/1\/sbae213\/61203737\/sbae213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/1\/sbae213\/61203737\/sbae213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:16:56Z","timestamp":1768630616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbae213\/7925816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,16]]},"published-print":{"date-parts":[[2026,1,16]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbae213","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2024,12,16]]},"article-number":"sbae213"}}